PORTLAND, Ore., Oct. 06, 2016 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCQB:ERGO) was informed by the American
Society of Nephrology (“ASN”) that its submission of “late breaking clinical trials” results has been accepted for presentation at
the ASN Kidney Week 2016 Annual Meeting November 17-20 in Chicago, at the McCormick Place Convention Center. The presentation
is titled: “ErgoD2 Medical Food Therapy: A Novel Strategy to Delay Progression of Chronic Kidney Disease (CKD).”
“The acceptance of our CKD clinical trial study for presentation is evidence of the Society’s interest in the potential of our
technology,” stated Marvin S. Hausman MD, Entia Chief Science and Technology Officer. It is indeed an honor for our Company
and we are looking forward to showing a large audience of nephrologists from the United States and the world the therapeutic value
of adding our ErgoD2® medical food to the CKD patient standard of care that is currently available.”
Chronic Kidney Disease takes a significant toll on the health of more than 25 million individuals in the U.S. alone.
Progression of the disease leads to dialysis, and eventually the need for a kidney transplant. The cost to the U.S.
Healthcare system was reported as $42.5 billion in 2009 by the National Institutes of Health, and has been growing at a compound
rate of +9.8% annually.
The product being tested is a specific proprietary blend of Entia’s patented ErgoD2 technology. Entia Biosciences is the
first company to develop, produce and market consumer products with all-natural formulas for the amino acid L-ergothioneine and
enhanced vitamin D2. This novel medical food is a supplement to a patient’s existing prescribed regimen of care and is
intended to increase kidney filtration rates, improve iron levels and increase production of red blood cells. If the study
proves successful, Entia’s ErgoD2 product formulation for Chronic Kidney Disease will provide patients with the first all-natural,
organic medical food product designed to improve the health and well-being of the patient, enhance the dietary management of the
disease and potentially slow its progression.
The application of medical foods containing ErgoD2 formulations is not limited to Chronic Kidney Disease; Entia believes that
ErgoD2’s ability to improve iron homeostasis has the potential to mitigate many other chronic disease conditions related to iron
dysfunction. Entia plans to address several disease markets, all characterized by dysfunctional iron disorders, in which it
believes its products may be of significant efficacy. These disorders are also associated with oxidative stress and
inflammation and include, but are not necessarily limited to, Anemia, Chronic Kidney Disease, Autism and various neurodegenerative
diseases, such as Parkinson's and Multiple Sclerosis.
About Entia Biosciences, Inc.
Entia (OTCQB:ERGO) discovers, scientifically validates, develops and markets patented, pharmaceutical-grade organic compounds
that include its revolutionary ErgoD2®. The Company is a leading authority on the clinical effects of oxidative
stress, iron-related disorders and free radical reactions in mammals; it is bringing this expertise to the nutraceutical and
medical foods markets. Entia also develops and markets health-related cosmeceuticals.
Entia Biosciences, Inc. is headquartered in Sherwood, Oregon, a Portland suburb.
Forward-Looking Statements
Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements
that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this
press release, and other risks identified in the filings by Entia Biosciences, Inc. with the Securities and Exchange
Commission. Further information on risks faced by the Company and its shareholders are detailed in the Form 10-K for the year
ended December 31, 2015 and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a
website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the
date indicated. Actual results, events or performance may differ materially. Entia does not undertake any obligation to
publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events.
Contact: Carl Johnson or Tim Timmins (844-559-9910)
